{"id":596956,"date":"2026-04-10T02:14:08","date_gmt":"2026-04-10T02:14:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/596956\/"},"modified":"2026-04-10T02:14:08","modified_gmt":"2026-04-10T02:14:08","slug":"where-is-the-value-amongst-asx-healthcare-shares","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/596956\/","title":{"rendered":"Where is the value amongst ASX healthcare shares?"},"content":{"rendered":"\n

In what has been a volatile<\/a> start to 2026, ASX healthcare shares have been amongst the sharemarket losers.\u00a0 <\/p>\n

The S&P\/ASX 200 Health Care Index (ASX: XHJ) has fallen almost 17% year to date.\u00a0<\/p>\n

However, there are opportunities to find value for investors.\u00a0<\/a> <\/p>\n

Let’s look at three ASX healthcare shares drawing positive outlooks from experts.\u00a0<\/p>\n

\"Doctor<\/p>\n

Image source: Getty Images<\/p>\n

Telix Pharmaceuticals Ltd (ASX: TLX<\/a>) <\/p>\n

Telix is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation.\u00a0 <\/p>\n

This process treats cancerous or diseased cells, an alternative approach to many cancer therapies, which also attack healthy tissue at the same time. <\/p>\n

Telix shares have rebounded over the past couple of months, rising 55% since mid February.\u00a0<\/p>\n

Telix shares rose in March largely because several value-driving catalysts hit at once<\/a>, improving both fundamentals and investor sentiment. <\/p>\n

However, they remain down 48% over the last year.\u00a0<\/p>\n

In good news for investors, brokers are expecting Telix shares to recover even further.\u00a0<\/p>\n

Recently, Bell Potter<\/a> retained its buy rating and $19 price target on this radiopharmaceuticals company’s shares.\u00a0<\/p>\n

From yesterday’s closing price of $13.64, this indicates a further upside of roughly 39%.\u00a0<\/p>\n

Mayne Pharma Group Ltd (ASX: MYX<\/a>) <\/p>\n

Mayne Pharma Group is another ASX healthcare stock that is down significantly from yearly highs.\u00a0<\/p>\n

It has fallen 32% year to date.\u00a0<\/p>\n

This includes a 6% decline yesterday, as investors may have reacted negatively to fresh tariff worries<\/a>. <\/p>\n

However, the company is confident the new tariffs <\/a>will<\/a>\u00a0have “no material impact” on its FY27 earnings profile.<\/p>\n

The stock price closed yesterday at $2.16, and after the recent fall, it may be another value play.<\/p>\n

Two analysts’ forecasts via TradingView have an average one-year price target of $5.75 on the stock, indicating more than 160% upside.\u00a0<\/p>\n

EBR Systems Inc (ASX: EBR<\/a>) <\/p>\n

EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation.\u00a0 <\/p>\n

The company’s Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart.<\/p>\n

It is down roughly 30% year to date. However, it is also drawing positive ratings from brokers.\u00a0<\/p>\n

Yesterday, the company released a preliminary version of its operating metrics.\u00a0<\/p>\n

The report <\/a>showed strong Q1 2026 growth in commercial cases.<\/p>\n

This prompted Bell Potter<\/a> to release updated guidance on this ASX healthcare stock along with a price target of $2, indicating a potential 194% rise.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"In what has been a volatile start to 2026, ASX healthcare shares have been amongst the sharemarket losers.\u00a0…\n","protected":false},"author":2,"featured_media":99264,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-596956","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/596956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=596956"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/596956\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/99264"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=596956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=596956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=596956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}